Find Progesterone Injection, Female Protection, Finished Medicine on Industry Directory, Reliable Manufacturer/Supplier/Factory from China.

Inquiry Basket (0)
Home > Products > Medical Antibiotics > Drug to Control of Serum Phosphorus Sevelamer Carbonate Tablet 800mg

Drug to Control of Serum Phosphorus Sevelamer Carbonate Tablet 800mg

Basic Info

Model No.:  DAWA1435

Product Description

Model NO.: DAWA1435 Usage Mode: For oral administration Shape: Tablet Pharmaceutical Technology: Chemical Synthesis Specifications: 800mg Trademark: NANOMAX Specification: GMP/WHO GMP/EURO GMP HS Code: 2941909000 Application: Internal Medicine State: Solid Type: Biological Products Name: Sevelamer Carbonate Tablet, Packing: 30tabs/Bottle Transport Package: 30tabs/Bottle Origin: France
Name Sevelamer Carbonate Tablet,
Strength 800mg
Package 30tabs/bottle

Sevelamer Carbonate Tablet,

Dosage and Administration 

Sevelamer carbonate is a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis. 

Starting dose of sevelamer carbonate is 0.8 or 1.6 grams administered orally three times per day with meals. 
Titrate by 0.8 g per meal in two week intervals as needed to obtain serum phosphorus target (3.5 to 5.5 mg/dL). 
Switch gram-for-gram among sevelamer formulations. Further titration may be necessary to achieve desired phosphorus levels. 

Tablets: 800 mg 
Powder: 0.8 g and 2.4 g packet 

Bowel obstruction. 

Serious cases of dysphagia, bowel obstruction, and perforation have been associated with sevelamer use, some requiring hospitalization and surgery. 

Most of the safety experience is with sevelamer tablets. The most frequently occurring adverse reactions in a short term study with sevelamer carbonate tablets (8-week cross-over) study were: nausea (3%) and vomiting (3%). In a short term study of sevelamer carbonate powder, adverse events were similar to those reported for sevelamer carbonate tablets. In long-term studies with sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, the most common adverse events included: vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%), abdominal pain (9%), flatulence (8%) and constipation (8%). 
Cases of fecal impaction and, less commonly, ileus, bowel obstruction and bowel perforation have been reported. 

Contact us if you need more details on Sevelamer. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Carbonate、Tablet. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Medical Antibiotics

Email to this supplier
  • *Subject:
  • To:

  • *Messages:
    Your message must be between 20-8000 characters